ClinicalTrials.gg
RecruitingNCT06906380Updated Oct 30, 2026

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

An observational study in Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory and MDS (Myelodysplastic Syndrome), sponsored by ARCE Therapeutics, Inc.. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by ARCE Therapeutics, Inc. · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
83rd of 126
49 · median 98
Started
2026
with 72 others
Observational
126 of 2,138
29 open now
Primary completion
2040-05
later than 453 of 461 live
Registered
2,038th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 83rd largest by planned enrollment of the 126 observational ones that give a count, is one of 73 that started in 2026, is one of 126 observational ones, reaches primary completion later than 453 of the 461 other live ones, and was the 2,038th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety of ARD103 cellular therapies

Read the detailed description

Participants who receive administration of ARD103 (i.e., a partial dose or a full dose) will roll into the LTFU study upon completion of the 24-month interventional study period (Study: ARD103_ARCE-CL-P-001), or after early discontinuation from the interventional study protocol. The LTFU study is a study intended to characterize long-term safety for 15 years post-ARD103 administration. Participants who complete the full 24-month interventional study period will undergo an additional 13 years of monitoring under the LTFU study. No IP will be administered during the LTFU study. The number and percentage of participants with ARD103 CAR-T cell therapy related AEs, SAEs, and AESIs will be recorded throughout the LTFU Period.

03

Conditions studied

  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia, in Relapsed or Refractory
  • MDS (Myelodysplastic Syndrome)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will comprise participants with R/R AML or MDS treated with ARD103. All subjects with AML or MDS who are enrolled in a parent study and were received ARD103 CAR-T infusion will be asked to participate in this long-term follow-up (LTFU) study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
  • The participant is able to understand and comply with protocol-required study procedures and has provided a written document.

Exclusion criteria

Exclusion Criteria:

  • There are no specific exclusion criteria for this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non Interventional

    All subjects with AML or MDS who are enrolled in a parent study and were exposed to ARD103 CAR-T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.

    Other: Non interventional study

Interventions

  • OtherNon interventional study

    Non Intervention, an observation LTFU study

06

What researchers measure

Primary outcomes

  1. The incidence and duration of AEs, SAEs, and AESIs related to ARD103 treatment.

    The number and percentages of participants experiencing TEAEs will be tabulated. Serious TEAEs will be summarized and AESIs will be summarized.

    Time frame: 15 years

Secondary outcomes

  1. The long-term efficacy of ARD103 in participants with R/R AML or MDS

    Overall survival (OS): the time from the infusion of ARD103 CAR-T in the parent study until death for any cause. Duration of Response (DOR): the time from the first recorded response after ARD103 infusion to the first recorded efficacy result of disease progression, relapse, or death due to any cause, whichever occurs first. PFS: the time from the infusion of ARD103 in the parent study to the first recorded response of disease progression, relapse, or death due to any cause, whichever occurs first.

    Time frame: 15 years

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2040, 168 months after the start.

Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 154. This study's planned 168 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → May 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
May 12, 2026was Mar 2026
Primary completionEst.
May 30, 2040
CompletionEst.
Oct 31, 2040
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Novant Health Cancer Institute · Charlotte, United Statesno status→Recruiting
  • Novant Health Cancer Institute · Winston-Salem, United Statesno status→Recruiting
  • MD Anderson Cancer Center · Houston, United Statesno status→Recruiting
Oct 30, 2026
Start date
Mar 15, 2026→May 12, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Novant Health Cancer Institute · Charlotte, United Statesno status→Recruiting
    • Novant Health Cancer Institute · Winston-Salem, United Statesno status→Recruiting
    • MD Anderson Cancer Center · Houston, United Statesno status→Recruiting
    Start date Mar 15, 2026→May 12, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06906380
Lead sponsor
ARCE Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
May 12, 2026
Primary completion
May 30, 2040 (estimated)
Completion
Oct 31, 2040 (estimated)
Last update
Oct 30, 2026

Study contacts

ARCE Therapeutics, Inc ARCE
Contact
contact@arcetherapeutics.com
+886-2-26581868

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion